Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab
Sign Up to like & getrecommendations! Published in 2019 at "Oncology"
DOI: 10.1159/000502910
Abstract: Background: It is unclear for whom new anti-human epidermal growth factor receptor 2 (anti-HER2) agents, such as pertuzumab and T-DM1, should be considered. We investigated prognostic factors before neoadjuvant chemotherapy (NAC) among HER2-positive invasive breast… read more here.
Keywords: post nac; cancer patients; breast cancer; prognostic factors ... See more keywords
PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Immunopathology and Pharmacology"
DOI: 10.1177/03946320221078433
Abstract: Objectives: To investigate the expression of programmed death-ligand 1 (PD-L1) in breast cancer in association with incomplete pathological response (PR) to neoadjuvant chemotherapy (NAC). Methods PD-L1 expression was evaluated using immunohistochemistry in post-operative, post-NAC samples… read more here.
Keywords: nac samples; breast; nac; expression ... See more keywords
Contralateral Prophylactic Mastectomy Use After Neoadjuvant Chemotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Surgical Oncology"
DOI: 10.1245/s10434-019-08038-8
Abstract: Background Neoadjuvant chemotherapy (NAC) for breast cancer increases breast-conserving surgery (BCS) rates, but many women opt for mastectomy with contralateral prophylactic mastectomy (CPM). Here we evaluate factors associated with CPM use in women undergoing mastectomy… read more here.
Keywords: use; cpm; neoadjuvant chemotherapy; post nac ... See more keywords
PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13040746
Abstract: Simple Summary Immune checkpoint inhibitors (ICI) are now part of the therapeutical arsenal for cancers at several sites and in several settings. PD-L1 expression is assessed to predict treatment response. We used immunohistochemistry (E1L3N clone)… read more here.
Keywords: negative breast; breast cancers; expression; post nac ... See more keywords